Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrante, K. L.
Right arrow Articles by Cudkowicz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrante, K. L.
Right arrow Articles by Cudkowicz, M.
Related Collections
Right arrow Amyotrophic lateral sclerosis
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2005;65:1834-1836
© 2005 American Academy of Neurology
Brief Communications

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

K. L. Ferrante, BA, J. Shefner, MD, PhD, H. Zhang, MS, R. Betensky, PhD, M. O'Brien, MPH, PT, H. Yu, MS, M. Fantasia, MPH, J. Taft, MPAS, PA, M. F. Beal, MD, B. Traynor, MD, K. Newhall, BS, P. Donofrio, MD, J. Caress, MD, C. Ashburn, RN, MSN, B. Freiberg, PT, C. O'Neill, BS, C. Paladenech, RRT, T. Walker, RN, BSN, A. Pestronk, MD, B. Abrams, RN, J. Florence, MHS, DPT, R. Renna, RN, J. Schierbecker, MHS, PT, B. Malkus, MHS, PT and M. Cudkowicz, MD, MSc

From Neurology Clinical Trials Unit (Drs. Traynor and Cudkowicz, K.L., Ferrante, M. O'Brien, Y. Yu, M. Fantasia, K. Newhall), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology (Dr. Shefner and J. Taft), SUNY Upstate Medical University, Syracuse, NY; Department of Biostatistics (Dr. Betensky and H. Zhang), Massachusetts General Hospital Biostatistics Center, Harvard Medical School, Boston; Department of Neurology and Neuroscience (Dr. Beal), Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY; Department of Neurology (Drs. Donofrio and Caress, C. Ashburn, B. Freiberg, C. O'Neill, C. Paladenech, T. Walker), Wake Forest University School of Medicine, Winston-Salem, NC; Department of Neurology (Dr. Pestronk, B. Abrams, J. Florence, R. Renna, J. Schierbecker, B. Malkus), Washington University School of Medicine, St. Louis, MO.

Address correspondence and reprint requests to Kimberly Ferrante, Massachusetts General Hospital, 13th Street, CNY 149, Room 2274, Charlestown, MA 02129; e-mail: kimberly.ferrante{at}umassmed.edu

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 13 issue to find the title link for this article.

Supported by the Mallinckrodt General Clinical Research Center at Massachusetts General Hospital, grant number M01-RR-01066, National Center for Research Resources, NIH, as well as the General Clinical Research Centers at Wake Forest University School of Medicine and Washington University School of Medicine (M01-RR00036, M01-RR07122) and by the Muscular Dystrophy Association.

Disclosure: The authors report no conflicts of interest.

Received April 11, 2005. Accepted in final form August 16, 2005.




This article has been cited by other articles:


Home page
 J. Nutr.Home page
N. Sumien, K. R. Heinrich, R. A. Shetty, R. S. Sohal, and M. J. Forster
Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice
J. Nutr., October 1, 2009; 139(10): 1926 - 1932.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ryu, J. Lee, S. W. Hagerty, B. Y. Soh, S. E. McAlpin, K. A. Cormier, K. M. Smith, and R. J. Ferrante
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
PNAS, December 12, 2006; 103(50): 19176 - 19181.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. J. Traynor, L. Bruijn, R. Conwit, F. Beal, G. O'Neill, S. C. Fagan, and M. E. Cudkowicz
Neuroprotective agents for clinical trials in ALS: A systematic assessment.
Neurology, July 11, 2006; 67(1): 20 - 27.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.